PROTAC BRD4 Degrader-12 is designed with ligands for von Hippel-Lindau and BRD4, facilitating targeted degradation of the BRD4 protein. This compound can be conjugated with antibodies against STEAP1 and CLL1, enhancing its specificity for degrading BRD4 in PC3 prostate cancer cells. The structural design allows for effective engagement with the ubiquitin-proteasome system for protein modulation.
Usually ships within 24 hours.